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Abstract
Background:  The nucleus accumbens (NAc) plays a critical role in amphetamine-produced
conditioned place preference (CPP). In previous studies, NAc basal and amphetamine-produced
DA transmission was altered by Group II mGluR agents. We tested whether NAc amphetamine
CPP depends on Group II mGluR transmission.
Results: NAc injections (0.5 µl/side) of the Group II mGluR antagonist (2 S)- a-ethylglutamic acid
(EGLU: 0.01–0.8 µg but not 0.001 µg) impaired CPP. The drug did not block the acute locomotor
effect of amphetamine.
Conclusion: Results suggest that Group II mGluRs may be necessary for the establishment of NAc
amphetamine-produced CPP. These receptors may also mediate other forms of reward-related
learning dependent on this structure.
Background
Metabotropic glutamate receptors (mGluRs) are impli-
cated in learning and synaptic plasticity [1]. mGluRs have
been classified into three groups: Group I, including
mGluR1 and mGluR5; Group II, including mGluR2 and
mGluR3; and Group III, including mGluR 4 and mGluR
6–8. Group I stimulates phospholipase C (PLC) and
phosphoinositide hydrolysis, whereas Group II and
Group III inhibit cyclic adenosine monophosphate
(cAMP) formation most likely through a Gi-type protein
[2,3]. Both cAMP and PLC are widely implicated in synap-
tic plasticity [4]. Through their activity on G-proteins and
other second messengers, mGluRs modulate ion channel
conductances, transmission through ligand-gated chan-
nels, as well as the activation of immediate early genes.
Therefore, mGluRs are well suited to provide a means
through which glutamate can induce synaptic changes at
the same synapses where it elicits fast responses. The role
of Group I mGluRs in learning and plasticity has been
characterized extensively. Group II mGluRs have received
less attention [1].
There is evidence suggesting a role for Group II in synaptic
plasticity in learning. Group II is involved in corticostri-
atal long term depression (LTD) in the nucleus
accumbens (NAc) [5]. Behavioral work implicates Group
II receptors in olfactory and fear learning [6,7] and in lever
pressing for food [8,9]. The reported Group II mGluR
modulation of reward-related learning is consistent with
the role of these receptors in downregulating the cAMP/
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PKA cascade[10]. cAMP-dependent protein kinase (PKA)
activation mediates the acquisition of learning [11] and of
reward-related learning in particular [12].
Both reward-related learning and addiction to psychos-
timulants critically involve NAc dopamine (DA) and
share many of the same intracellular signals [12-14].
Glutamate release is necessary for amphetamine- and
cocaine-produced conditioned place preference (CPP)
[15,16] and systemic mGluR antagonists impair cocaine
self-administration in rats [17]. The role of Group II
mGluRs in the acquisition of psychostimulant reward has
not been addressed in pharmacological studies.
Group II mGluRs modulate DA transmission. Locally
administered agonists reduce, whereas locally adminis-
tered antagonists increase NAc DA levels [18,19]. Group II
mGluR agonists also modulate amphetamine-produced
DA release, enhancing it in drug-naïve baboons [20] and
impairing it in amphetamine-sensitized rats [21]. In a
recent study mGluR2 receptor knockout mice showed
enhanced cocaine-produced CPP [22]. Results showing
that Group II blockade enhanced basal DA release [19]
suggest that mGluR2-/- mutants may exhibit behaviors
related to psychostimulant sensitization [23], explaining
the hyperlocomotion in a novel environment and
enhanced cocaine CPP observed in these mice. The acute
role of Group II mGluRs in the acquisition of NAc psycho-
stimulant-produced CPP has not been investigated.
In the present studies, we used CPP [24] to test the
hypothesis that NAc DA-mediated learning depends on
Group II mGluRs. A Group II mGluR antagonist was
administered directly into NAc and the acquisition of CPP
based on NAc amphetamine was assessed. We found that
CPP was antagonized by the Group II antagonist. Part of
this research has been presented in abstract form [25].
Results
Histology
A total of 97 rats completed testing. Three rats failed to
complete the study due to illness or technical problems.
There was no relationship between the type and dose of
drug and illness observed in these animals. Cannula
placements were assessed for the remaining rats. A total of
24 rats was excluded leaving 73 rats for subsequent analy-
ses. Figure 1 shows the location of cannula tips for all rats
included in the analyses. Animals were classified as hits if
the tips of both cannulae were located in the core or shell
region of NAc.
Time spent on each side during pre-exposure
The interpretation of CPP results is not straightforward if
animals have a natural avoidance of the to-be-drug-paired
side. In such a case, an apparent increase in time spent on
that side after conditioning may be the result of decreased
avoidance of the drug-paired side or simply habituation
[24]. To check for bias, we averaged time spent on the side
that would be paired with drug across the 3 habituation
days and compared it to time spent on the side that would
be paired with vehicle for each group. Paired samples t-
tests revealed non-significant differences for all groups
(see Table 1). Thus, rats did not avoid the to-be-drug-
paired side during habituation and the CPP paradigm was
unbiased.
Drawings of coronal sections through the nucleus accumbens  indicating sites of infusion Figure 1
Drawings of coronal sections through the nucleus 
accumbens indicating sites of infusion. Injections of 
EGLU (0.0, 0.001, 0.01, 0.4 or 0.8 µg/0.5 µl/side) were fol-
lowed by amphetamine injections (20 µg/0.5 µl/side) before 
conditioning sessions or 0.01 µg EGLU alone before condi-
tioning sessions. Injector sites may appear fewer than the 
reported number of rats because of overlap of placements. 
Numbers to the left indicate distance (in millimeters) from 
bregma.BMC Neuroscience 2006, 7:43 http://www.biomedcentral.com/1471-2202/7/43
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Tunnel time
A change in the time spent in the drug-paired side from
habituation to test cannot be interpreted unambiguously
as a change in place preference if time spent in the tunnel
also changes. Thus, additional analyses were performed to
compare tunnel time before and after conditioning (see
Table 1). No significant differences were found.
Place conditioning
To induce CPP NAc amphetamine was paired with one
side of the apparatus over four conditioning days. EGLU
was injected into NAc approximately ten minutes before
amphetamine. Vehicle alone was paired with the other
side of the apparatus on alternate days. CPP was analyzed
using a dose (0.0, .001, .01, .4, .8 µg, or .01 alone) × phase
(habituation vs. test) mixed ANOVA with phase as the
repeated factor and time spent on the drug-paired side as
the dependent variable. The ANOVA yielded a main effect
of phase [F(1, 67) = 5.362, p < .05] and a dose × phase
interaction [F(5, 67) = 2.77, p < .05]. A one-way simple
effects between-subjects ANOVA testing the effect of dose
during the habituation session was not significant. How-
ever, a one-way simple effects ANOVA testing the effect of
dose during the test session produced a main effect of
dose [F(5, 67) = 2.99, p  < .05]. Pairwise comparisons
revealed that on the test day rats conditioned with
amphetamine alone spent more time on the drug-paired
side than rats conditioned with amphetamine plus 0.4 µg
of EGLU. Rats conditioned with amphetamine plus the
lowest EGLU dose (0.001 µg) spent more time on the
drug-paired side compared to all other groups except the
group conditioned with amphetamine alone (Fisher LSD
posthoc tests; all ps < .05). This confirmed the hypothesis
that EGLU impairs CPP acquisition. Rats receiving 0.01 µg
of EGLU but no amphetamine showed no significant pref-
erence or avoidance (Figure 2).
Locomotor activity
Locomotor activity during conditioning sessions was ana-
lyzed for EGLU doses on the four amphetamine and four
saline conditioning days yielding a dose (0.0, 0.001, 0.01,
0.4, 0.8 µg, 0.01 µg alone) × phase (amphetamine vs.
saline) × day (4 days per phase) 3-way mixed ANOVA
with phase and day as the within-subjects factors and total
number of beam breaks per session as the dependent var-
iable. The analysis revealed main effects of phase [F(1, 67)
= 100.72, p < .001] and dose [F(5, 67) = 12.50, p < .001]
and dose × phase [F(5, 67) = 5.47, p < .001] and dose ×
phase × day [F(15, 201) = 2.31, p < .01] interactions. In
the drug phase, there was only a main effect of EGLU dose
[F(5, 67) = 8.69, p < .001]. Animals receiving ampheta-
mine or amphetamine plus EGLU (0.001, 0.01, 0.4 or 0.8
Time (+ SEM) spent on the drug-paired side during the 15  min pre-exposure and the test sessions Figure 2
Time (+ SEM) spent on the drug-paired side during 
the 15 min pre-exposure and the test sessions. Testing 
occurred after conditioning with amphetamine (20 µg) and 
the Group II mGluR antagonist EGLU (0.0–0.8 µg) adminis-
tered locally into NAc (bilaterally in 0.5 µl vehicle). One 
group received 0.01 µg EGLU alone, i.e. no amphetamine was 
administered before conditioning sessions. See Table 1 for 
number of animals per group. aSignificantly higher than time 
spent on drug-paired side on test day for rats receiving 0.4 
µg of EGLU. bSignificantly higher than time spent on drug-
paired side on test day for rats receiving 0.01–0.8 µg of 
EGLU.
Table 1: Mean (± SEM) time (sec) spent on the drug-paired and vehicle-paired side before conditioning and in the tunnel before and 
after conditioning. The conditioned place preference paradigm was unbiased.
Dose of EGLU/0.5 µl/side N Time in drug-paired side 
before conditioning
Time in veh-paired side 
before conditioning
Tunnel time before 
conditioning
Tunnel time after 
conditioning
0.0 µg 9 401.6 (17.0) 446.1 (19.1) 52.3 (5.1) 48.8 (9.4)
0.001 µg 22 418.7 (19.9) 421.5 (20.1) 59.7 (3.7) 68.7 (6.5)
0.01 µg 12 431.4 (30.2) 413.6 (31.9) 58.6 (5.4) 55.1 (5.8)
0.4 µg 9 411.2 (22.0) 431.2 (24.4) 57.6 (4.7) 51.4 (6.4)
0.8 µg 9 418.2 (23.0) 439.1 (25.1) 48.0 (4.0) 52.3 (3.6)
0.01 µg alone 12 418.8 (20.4) 416.6 (21.1) 64.6 (6.0) 69.5 (8.1)
Abbreviations: Veh = vehicle.
Note. None of the pairs of means are significantly different.BMC Neuroscience 2006, 7:43 http://www.biomedcentral.com/1471-2202/7/43
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µg) showed higher locomotor activity than animals con-
ditioned with 0.01 µg of EGLU alone (all ps < .05, Fisher
LSD posthoc tests). In the saline phase, there was a main
effect of EGLU dose [F(5, 67) = 5.35, p  < .001]. The
amphetamine group showed higher activity than the 0.01,
0.01 alone and 0.8 groups. The 0.001 µg group showed
higher activity than the higher EGLU doses (0.01, 0.4, 0.8
and 0.01 alone; all ps < .05, Fisher LSD posthoc tests). Thus
amphetamine increased locomotor activity both in
groups that showed a CPP (0 and 0.001 doses) and in
groups that did not (0.01, 0.4 and 0.8 doses). Although
activity was significantly lower in all groups on vehicle
days, the two groups that showed a place preference had
higher locomotion in the drug-free phase (Figure 3).
Discussion
In the present studies NAc amphetamine injections pro-
duced CPP. This effect was impaired by a Group II mGluR
antagonist. The CPP paradigm was unbiased; rats did not
show a systematic preference for one side of the apparatus
over the other before conditioning. Also, the time rats
spent in the tunnel before and after conditioning did not
change significantly showing that increases in time spent
on the drug-paired side were in fact due to changes in pref-
erence. If EGLU produced conditioned place avoidance
on its own then simple additivity of this putative effect
and the positive effect of amphetamine might explain the
observed pattern of results. To test this, we injected one
group of rats with EGLU alone on what would normally
have been an amphetamine plus EGLU day using an
EGLU dose that was found to affect amphetamine CPP
(0.01 µg). On test day these rats did not show a preference
or avoidance for the chamber normally paired with
amphetamine. Thus putative place conditioning proper-
ties of EGLU do not appear to account for the observed
results. Amphetamine stimulated locomotor activity.
Activity among groups differed in drug-free vehicle ses-
sions, with the groups that had received amphetamine
alone or amphetamine plus 0.001 µg EGLU into NAc dur-
ing conditioning being more active.
Groups that showed the CPP effect also showed higher
activity in the vehicle phase. It is difficult to explain this
observation. We know of no reports of a relationship
between activity on vehicle  conditioning days and the
presence of a CPP effect. In our work we have repeatedly
observed locomotor stimulation on drug  conditioning
days in groups that subsequently showed a CPP and
groups that did not. Further studies are needed to assess
the reliability of this finding and of activity differences
among groups on vehicle conditioning days.
EGLU administration did not affect the acute increases in
locomotor activity produced by amphetamine in the drug
phase. EGLU has been reported to impair NAc ampheta-
mine-produced locomotion using an amphetamine dose
of 2.5 µg/0.5 µl/side [26]. We have previously reported
that NAc amphetamine doses ranging from 5.0–20.0 µg
produced similar levels of locomotor stimulation but a
dose-dependent CPP effect (Beninger et al., 2003). For the
present study we chose a dose of amphetamine (20 µg)
that produced a significant CPP effect; this dose was eight
times higher than the dose needed to produce motor stim-
ulation in the study of Kim et al. (2000). The doses of
EGLU (0.09 and 0.88 µg) that they used to reduce the
locomotor stimulatory effect of amphetamine were com-
parable to the higher doses used here. Our failure to rep-
licate their findings probably relates to our use of a
substantially higher dose of amphetamine.
The NAc can be subdivided into core and shell subregions
[27] and a number of studies suggest that these subregions
may be differentially involved in reward-related learning
Mean (+SEM) activity counts (per 30 min) during conditioning  sessions Figure 3
Mean (+SEM) activity counts (per 30 min) during 
conditioning sessions. Activity counts on the drug- (left 
panel) and vehicle-paired (right panel) sides are shown. 
Groups were treated with 0.0 – 0.8 µg EGLU followed by 
amphetamine (20 µg) immediately before placement on the 
corresponding side of the conditioning apparatus. One group 
received 0.1 µg EGLU alone, i.e. no amphetamine was admin-
istered before conditioning sessions. See Table 1 for number 
of animals per group.
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and locomotion [28-32]. Our data did not permit a direct
investigation of the relative contribution of the two subre-
gions. An attempt was made to assess the possible role of
the core and shell by separating the groups into core and
shell placements and performing post hoc analyses. How-
ever only a few rats had both cannulae located within the
core subregion. These rats were distributed unevenly
among the groups making it impossible to statistically
analyze the effect of region. It should be noted however
that we have previously reported significant ampheta-
mine CPP using the same vehicle volume and injection
parameters with placements in both the core and shell
[33]. In other work, lower injection volumes have been
used to study the differential role of each subregion [34].
A more thorough investigation of the role of NAc subre-
gions in CPP produced by local injections of ampheta-
mine is awaited.
Dopaminergic innervation of the NAc, among other struc-
tures, has been widely implicated in natural appetitive
behaviors and addiction [35]. NAc plays a critical role in
the acquisition of amphetamine-produced CPP [36,37].
DA modulation of corticostriatal glutamatergic projec-
tions is believed to underlie reward-related learning [38-
40]. mGluRs may be involved in this modulation. Group
I blockade impaired corticostriatal synaptic plasticity [41].
Group I mGluRs have been implicated in the acquisition
of drug reward [42,43] and in mediating DA agonist-pro-
duced changes in intracellular cascades widely implicated
in memory and plasticity [1,44-46]. While Group II
mGluRs have not been investigated as thoroughly in this
context, several behavioral studies have demonstrated a
role for Group II mGluRs in learning. Group II mGluR
activation rescued a nonselective mGluR antagonist-pro-
duced impairment of the spontaneous improvement in
lever-pressing for food in mice [9]. Group II activation
also impaired lever-pressing for food in rats although this
effect was schedule-dependent [8]. In a mouse study, sys-
temic cocaine-produced CPP was enhanced in Group II
mutants [22]. In contrast, we found that acute administra-
tions of the Group II mGluR antagonist EGLU impairs the
acquisition of NAc amphetamine CPP. Our results are not
in disagreement with this study. The mutants showed a
behavioral spectrum consistent with psychostimulant
sensitization, including enhanced cocaine behavioral sen-
sitization, hyperlocomotion in a novel environment and
enhanced DA release after a systemic cocaine injection.
This observation is supported by work showing that a
locally administered mGluR II antagonist increased basal
DA levels [19]. The observed phenotype may therefore
reflect long term adaptations produced by changes in stri-
atal DA rather than acute effects of Group II mGluR block-
ade.
Little is known about the mechanism though which
Group II mGluRs modulate the acquisition of reward-
related learning. Group II mGluR antagonist-produced
impairments in the acquisition of amphetamine CPP may
be mediated by effects on PKA. The acquisition of reward-
related learning involves DA receptor-mediated PKA acti-
vation [12]. Both the inhibition and direct activation of
PKA impair reward-related learning and learning in other
tasks [6,33,47]. In an in vitro study, a group II antagonist
enhanced the stimulation of cAMP formation by forskolin
[48]. Both a Group II agonist and antagonist impaired
learning in a step-down avoidance task [6]. The agonist-
produced impairment was rescued by coinfusion of for-
skolin, suggesting that mGluR II may act in synchrony
with other receptors including mGluR I and DA1-like
receptors to produce an optimal level of PKA activation. In
fact, work from our lab [33,49] has shown that activation
of the cAMP/PKA cascade impairs NAc amphetamine-pro-
duced CPP – a finding that may parallel the effects of a
mGluR antagonist on a tonically active Group II mGluR
signal.
Group II mGluRs may modulate plasticity by altering
NMDA-DA receptor interactions in NAc. NMDA receptors
are necessary for DA-mediated reward-related learning
[50]. Group II activation alters NMDA-produced intracel-
lular signaling in striatal neurons [51]. Group II inhibi-
tion impairs NMDA-dependent hippocampal LTD [52]
and corticostriatal NAc LTD [5]. NAc LTD may mediate
NAc-dependent learning and psychostimulant-produced
plasticity [53,54]. Reward-related learning is thought to
be mediated by the selective strengthening of behaviorally
relevant corticostriatal inputs to striatum [38-40]. Perhaps
Group II mGluRs are involved in the selective depression
of synapses not related to current input in effect adjusting
the gain of behaviorally relevant glutamatergic efferents to
the NAc [54]. Further work will have to test this intriguing
possibility.
Conclusion
We investigated the role of Group II mGluRs in reward-
related learning using the CPP paradigm. This report is the
first to test the effects of a Group II mGluR antagonist
applied locally in the brain on the acquisition of CPP pro-
duced by NAc injections of amphetamine. We showed
that the antagonist impaired NAc amphetamine-pro-
duced CPP. The results are consistent with previous
research showing a role for mGluRs in memory and plas-
ticity and DA-mediated reward-related learning. Group II
mGluR modulation of DA effects in the NAc may involve
changes in PKA activation, changes in NMDA signaling or
both.BMC Neuroscience 2006, 7:43 http://www.biomedcentral.com/1471-2202/7/43
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Methods
Animals and surgery
Male Wistar rats (Charles River, St. Constant, Quebec)
weighing between 200–250 g on arrival were housed in
pairs on a 12-hr reversed light-dark cycle (lights on at
19:00 hr) at an average temperature of 21°C, humidity
40–70%. Water and food (LabDiet 5001, PMI Nutrition
Intl, Brentwood, MO) were freely available. Rats were
handled for about 1 min on each of 5 consecutive days
after arrival. The experimental protocol was approved by
the Animal Care Committee at Queen's University. All
animals were treated in full compliance with the Animals
for Research Act and relevant guidelines set by the Cana-
dian Council on Animal Care.
Approximately one wk after arrival at the colony, rats were
anesthetized in an induction chamber using an inhalable
anesthetic (5% isoflurane; Bimeda, Cambridge, ON)
mixed with oxygen in a vaporizer system (Benson,
Merkham, ON) and administered at 1.0 l/min. Anesthe-
tized animals were fitted to a stereotaxic apparatus and
isoflurane was administered at a concentration of 2% or
as needed to maintain anesthesia. The head was adjusted
so that lambda and bregma were on the same horizontal
plane. For analgesia, buprenorphine hydrochloride in
solution (0.15 mg/kg; Reckitt & Colman, Richmond, VA)
was injected subcutaneously preoperatively. Ketoprofen
(1.5 mg/kg; Merial, Baie d'Urfé, QC) was injected imme-
diately after surgery and on three subsequent days postop-
eratively. The experimenter shaved the rat's head and
applied betadine solution with a cotton tip applicator
before incising the skin. Holes were drilled into the skull
and 23 gauge (0.64 mm diameter) stainless-steel guide
cannulae were chronically implanted bilaterally into the
NAc, with coordinates: 1.6 mm anterior to bregma, 1.4
mm lateral to the midline and 6.7 mm ventral from the
skull surface [55]. The guide cannulae were held in place
by four stainless-steel screws and dental acrylic. Stainless
steel wire stylets (0.31 mm diameter) flush with the end
of the guide cannulae were put in place to prevent occlu-
sion. Rats were allowed approximately one wk to recover
before the start of behavioral testing. Behavioral data were
analyzed if the tips of the cannulae were located in the
core or shell region of NAc.
Drug infusion
The Group II mGluR antagonist (2 S)- a-ethylglutamic
acid (EGLU; Tocris, Ellisville, MO) was dissolved in saline
before the beginning of the experiment and stored at -
20°C. The pharmacological properties of this agent have
been well documented. EGLU impaired presynaptic
mGluR agonist-produced motoneuron depolarization
believed to be mediated by Group II mGluRs and inhib-
ited mGluR agonist binding in mGluR2-transfected cell
membranes [56].
Amphetamine sulfate (USP, Rockvill, MD) was dissolved
in saline daily before each set of injections. Central injec-
tions into the NAc were made with a microinfusion pump
(KD Scientific, Holliston, MA). Injectors were glued to
polyethylene tubing (0.75 mm o.d.) filled with distilled
water. The tubing was connected to two 10 µl microsy-
ringes (Microliter #701; Hamilton, Reno, NV) mounted
on the microinfusion pump. Drugs were backloaded into
the injectors by aspiration with the two syringes. Rats were
hand-held as the experimenter removed the stylets from
the guide cannulae and inserted the two injectors (0.31
mm o.d.). The injectors projected 1.2 mm beyond the
guide cannulae.
EGLU (0.001, 0.01, 0.4 or 0.8 µg/0.5 µl/side) was injected
bilaterally over 30 sec. The highest EGLU dose was similar
to a dose previously reported to impair NAc ampheta-
mine-produced locomotion [26]. After the drug was deliv-
ered, the injectors were left in place for another 30 sec to
facilitate diffusion, after which they were slowly retracted
from the guide cannulae. Amphetamine (20.0 µg/0.5 µl/
side) was injected approximately 10 min later using the
same procedure. This amphetamine dose was much
higher than the one reported by Kim et al. (2000) and has
been found to produce reliable CPP in previous studies
from our lab (e.g. [49,57]). Place conditioning began
immediately after amphetamine injection. Groups were
tested drug-free.
Apparatus
The 4 testing chambers each consisted of two rectangular
compartments (38 × 27 × 34 cm) connected with a tunnel
(8 × 8 × 8 cm). Two different spatial features were varied
across the 4 testing chambers. The compartment walls
were either urethane-sealed wood or alternating 1 cm-
wide black and white vertical stripes and were covered
with clear Plexiglas. The floor was either wire bars 1 cm
apart running perpendicular to the tunnel, or a wire grid
with openings of 1 cm2. This resulted in 4 possible com-
partment types, distributed as left or right compartment
across 4 different testing chambers. Each compartment
had a Plexiglas top with a number of circular ventilation
holes. The tunnel was fitted with guillotine-type doors,
which could be closed to prevent movement from one
compartment to the other. Two infrared emitters and
detectors (height 5.0 cm) in each compartment and 2 in
the tunnel (height 5.0 cm) were used to monitor move-
ment between and within compartments and to record
time spent in each compartment and the tunnel. The
number of beam breaks during conditioning sessions was
used as a measure of locomotion. Each of the 4 testing
chambers was housed in a dimly lit (7.5 Watt), sound-
attenuated and ventilated wooden box. Indirect light
reached the rat though the Plexiglas tops of the compart-
ments. Data from the sensors were collected on a 6809BMC Neuroscience 2006, 7:43 http://www.biomedcentral.com/1471-2202/7/43
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microcontroller using custom made software and trans-
ferred to a Macintosh computer for analyses. For further
details of the apparatus see [58].
Behavioral procedure
Training and testing occurred during the day (7:00–19:00
hr). Rats were tested in groups of 4 using a different testing
chamber for each rat. The experimental protocol consisted
of 3 habituation sessions, 8 conditioning sessions, and 1
test session. Each rat completed one session per day for a
total of 12 days.
Habituation
At the start of each 15-min session the rat was placed in
one compartment of the box – left compartment for half
the rats and right compartment for the other half. Tunnel
doors were open allowing the animals to move freely
between the two compartments. Activity sensors recorded
the amount of time spent on each side and in the tunnel.
Conditioning
Over 8 30-min sessions carried out on 8 consecutive days,
mGluR antagonists and amphetamine were injected into
the NAc on days 1, 3, 5 and 7, and vehicle on days 2, 4, 6
and 8. Injection of the mGluR antagonist was followed by
an injection of amphetamine approximately 10 min later.
Rats received only one injection on vehicle days. Immedi-
ately after amphetamine or vehicle injection, depending
on conditioning day, the rat was placed in one of the two
compartments with the tunnel doors closed preventing
movement into the other compartment or the tunnel.
Half the rats were confined to the left side on drug days
and to the right side on vehicle days. The other half were
confined to the right side on drug days and to the left side
on vehicle days. In this way, any given compartment was
paired with drug for some animals and with vehicle for
others. Number of beam breaks was recorded for each rat
to assess locomotion.
Six groups were tested. Five groups received amphetamine
(20 µg/0.5 µl/side) immediately before placement into
the conditioning compartment; these injections were pre-
ceded 10 min earlier by saline or EGLU doses of 0.001,
0.01, 0.4 or 0.8 µg/0.5  µl/side. One additional group
received EGLU (0.01 µg) 10 min before and saline imme-
diately before placement into the conditioning compart-
ment. This group assessed possible effects of EGLU alone
on side preference.
Testing
Testing occurred on the day immediately following condi-
tioning. The session lasted 15 min and was identical to
habituation sessions. The start side was the same for each
rat on test and habituation days. Time spent on each side
and in the tunnel was recorded.
Data analysis
Paired samples t-tests were used to compare tunnel time
before and after conditioning. To check for side bias,
another set of t-tests compared time spent on the drug-
paired side to time spent on the vehicle-paired side before
conditioning. The amount of time spent on the drug-
paired side was averaged across the 3 habituation days.
CPP was analyzed using a mixed dose × phase (habitua-
tion vs. test) analysis of variance (ANOVA) followed by
restricted ANOVA and pair-wise comparisons. In addi-
tion, the number of beam breaks for each rat on each of
the 8 conditioning days was summed and used as an
index of motor activity. Activity data were analyzed using
a dose × session type × day mixed ANOVA.
Histology
After completion of the experiment, rats were placed in an
airtight chamber and euthanized with CO2. Brains were
removed and preserved in a 10% formalin solution for at
least 72 hrs. Coronal sections 60 µm thick from through-
out the cannulated region were obtained by slicing the
brains on a cryostat at -20°C. The sections were mounted
on gelatin-coated glass slides and stained with cresyl vio-
let. Judgments about the cannulae placements in the NAc
were made by an observer who was blind to the results for
individual animals. Brains with cannula tips in the shell
and/or core regions of the NAc were included in subse-
quent analyses.
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